A Phase II Study of Linperlisib (YY-20394) in Patients With Relapsed or Refractory Peripheral T/NK Cell Lymphoma
This is a Phase II, single-arm study to evaluate the efficacy, safety, and PK of oral linperlisib (YY-20394) monotherapy in adult patients with R/R Peripheral T/NK Cell Lymphoma. The study will be conducted at approximately 15 sites in United States.
Peripheral T/NK Cell Lymphoma (R/R PTCL)
DRUG: YY-20394
overall response rate (ORR), Overall response rate (ORR = CR + PR), from start of treatment to first documented response, measured by Lugano 2014 Response Criteria for NHL (Cheson 2014), Throughout the study for approximately 2 years
duration of response (DOR), DOR, defined as time from first documentation of a response (PR or CR) to the first documented disease progression or death due to any cause, whichever occurs first, for those patients with a PR or CR., Throughout the study for approximately 2 years|progression-free survival (PFS),, PFS, defined as the time from start of treatment to first documented disease progression or death due to any cause, whichever occurs first., Throughout the study for approximately 2 years|Overall survival (OS), Throughout the study for approximately 2 years|Time to response (TTR), Throughout the study for approximately 2 years|AE, Incidence of Adverse events (AEs) using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 5.0, Throughout the study for approximately 2 years|AUClast, PK parameters, Throughout the study for approximately 2 years|AUCinf, PK parameters, Throughout the study for approximately 2 years|Cmin, PK parameters, Throughout the study for approximately 2 years|Cmax, PK parameters, Throughout the study for approximately 2 years|T1/2, PK parameters, Throughout the study for approximately 2 years|Tmax, PK parameters, Throughout the study for approximately 2 years
This is a Phase II, single-arm study to evaluate the efficacy, safety, and PK of oral linperlisib (YY-20394) monotherapy in adult patients with R/R Peripheral T/NK Cell Lymphoma. The study will be conducted at approximately 15 sites in United States.